Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Assets Average (2020 - 2025)

Historic Assets Average for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to $1.1 billion.

  • Kymera Therapeutics' Assets Average rose 2000.41% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2000.41%. This contributed to the annual value of $776.9 million for FY2024, which is 3180.11% up from last year.
  • Kymera Therapeutics' Assets Average amounted to $1.1 billion in Q3 2025, which was up 2000.41% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Assets Average ranged from a high of $1.1 billion in Q3 2025 and a low of $449.5 million during Q2 2021
  • Moreover, its 5-year median value for Assets Average was $608.5 million (2023), whereas its average is $702.7 million.
  • Its Assets Average has fluctuated over the past 5 years, first tumbled by 913.89% in 2023, then soared by 7842.49% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Assets Average (Quarter) stood at $624.2 million in 2021, then decreased by 0.54% to $620.8 million in 2022, then decreased by 9.14% to $564.1 million in 2023, then skyrocketed by 78.42% to $1.0 billion in 2024, then increased by 10.94% to $1.1 billion in 2025.
  • Its Assets Average stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $948.2 million for Q1 2025.